Digestive diseases and sciences

Cost-Effectiveness of AI Screening for Risky Fatty Liver Disease and Severe Liver Scarring in the US Population

Updated

Abstract

Over 10 years, AI + transient elastography (TE) provided an incremental gain of 0.107 QALYs compared to no screening.

  • AI + TE achieved an Incremental Cost-Effectiveness Ratio (ICER) of $38,916 per QALY when using semaglutide.
  • FIB-4 + TE and TE-only strategies had ICERs exceeding $72,500 per QALY for semaglutide, indicating lower cost-effectiveness.
  • The probability that AI + TE was cost-effective surpassed 90% at the $100,000 per QALY threshold for semaglutide.
  • Semaglutide consistently demonstrated greater cost-effectiveness than resmetirom across all screening strategies.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declarations. Conflict of interest: The authors declare no competing interests.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free